论文部分内容阅读
在冠状动脉粥样硬化性心脏病(简称冠心病)一级和二级预防中调脂治疗可以降低心血管疾病的发病率和病死率。使用他汀类药物降低低密度脂蛋白的水平仍然是治疗的首要目标。对于二级预防的患者,即患有冠心病或冠心病等位症,推荐积极地降低低密度脂蛋白,尽管它的精确目标值仍在讨论中。对于冠心病的初级预防,即具有冠心病易患因素的患者降低低密度脂蛋白的水平仍然是必要的。在临床实验结果中证实,对于那些中危到高危的患者他汀类治疗获益较大,而低危的患者获益较小。
Lipid-lowering treatment of primary and secondary prevention of coronary atherosclerotic heart disease (referred to as coronary heart disease) can reduce the incidence of cardiovascular disease and mortality. The use of statins to lower the level of LDL remains the primary goal of treatment. For patients with secondary prevention, who have coronary heart disease or coronary heart disease, it is recommended to aggressively lower LDL, although its exact target value is still under discussion. For the primary prevention of coronary heart disease, that is, patients with coronary heart disease risk factors to reduce the level of low-density lipoprotein remains necessary. In clinical trials, statin therapy has been shown to benefit patients who are critically ill at high risk, whereas patients at low risk have shown less benefit.